Cargando…
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial
IMPORTANCE: There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. OBJECTIVE: To...
Autores principales: | Howard, Robert, Zubko, Olga, Bradley, Rosie, Harper, Emma, Pank, Lynn, O’Brien, John, Fox, Chris, Tabet, Naji, Livingston, Gill, Bentham, Peter, McShane, Rupert, Burns, Alistair, Ritchie, Craig, Reeves, Suzanne, Lovestone, Simon, Ballard, Clive, Noble, Wendy, Nilforooshan, Ramin, Wilcock, Gordon, Gray, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865324/ https://www.ncbi.nlm.nih.gov/pubmed/31738372 http://dx.doi.org/10.1001/jamaneurol.2019.3762 |
Ejemplares similares
-
Efficacy of Antidepressants for Depression in Alzheimer’s Disease: Systematic Review and Meta-Analysis
por: Orgeta, Vasiliki, et al.
Publicado: (2017) -
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
por: Banerjee, Sube, et al.
Publicado: (2021) -
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
por: Howard, Robert, et al.
Publicado: (2018) -
Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
por: Garwood, Claire J., et al.
Publicado: (2010) -
Minocycline-induced hyperpigmentation
por: Fiscus, Valena, et al.
Publicado: (2014)